CNS Pharmaceuticals, Inc. (CNSP) 10-Year Financial Performance & Capital Metrics

CNSP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.Show more

Revenue $0
EBITDA -$15M +21.0%
Net Income -$15M +21.2%
EPS (Diluted) -38.87 +35.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -1703.39% -67.2%
ROIC -
Debt/Equity 0.05
Interest Coverage -924.50 +32.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Share count reduced 94.9% through buybacks
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM23.37%

EPS CAGR

10Y-

5Y-

3Y-

TTM79.36%

ROCE

10Y Avg-544.62%

5Y Avg-631.8%

3Y Avg-976.8%

Latest-1708.45%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.55B	7.62	54.43	55.85%	3.98%	15.63%	0.35%	1.02
EXELExelixis, Inc.	12.13B	45.23	25.70	18.49%	29.63%	31.37%	5.23%	0.09
INBXInhibrx Biosciences, Inc.	1.1B	75.93	0.65	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.16B	6.31	-2.99		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.4B	8.07	-3.42	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.1B	11.25	-6.15			-33.24%		0.01
ZLABZai Lab Limited	2.17B	19.61	-7.54	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.67B	12.39	-10.41	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	1.96K	11.1K	13.07K	11.76K	4.13K	3.31K
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-1.96K	-11.1K	-13.07K	-11.76K	-4.13K	-3.31K
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-4.68%	-0.18%	0.1%	0.65%	0.2%
Operating Expenses+	215.1K	881.79K	3.83M	9.44M	14.47M	14.92M	18.86M	14.9M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	182.47K	860.52K	1.98M	4.38M	4.67M	5.62M	4.77M	5.61M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	32.64K	21.27K	1.85M	5.06M	9.81M	9.3M	14.1M	9.29M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	-4.13K	0
Operating Income+	-516.25K	-881.79K	-3.83M	-9.45M	-14.49M	-14.93M	-18.87M	-14.9M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.71%	-3.35%	-1.47%	-0.53%	-0.03%	-0.26%	0.21%
EBITDA+	0	0	-3.83M	-9.44M	-14.47M	-14.92M	-18.86M	-14.9M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-1.47%	-0.53%	-0.03%	-0.26%	0.21%
D&A (Non-Cash Add-back)	516.25K	881.79K	1.96K	11.1K	13.07K	11.76K	4.13K	3.31K
EBIT	-516.25K	-7.35M	-3.83M	-9.45M	-14.49M	-15.27M	-18.87M	-14.84M
Net Interest Income+	-4.26K	-46.7K	-44.23K	-3.26K	-9.28K	-7.03K	13.88K	44.14K
Interest Income	0	0	44	3	9	7	27.69K	60.26K
Interest Expense	4.26K	46.7K	44.23K	3.26K	9.29K	7.03K	13.8K	16.12K
Other Income/Expense	-4.26K	-6.51M	-44.23K	-3.26K	-9.29K	-341.17K	13.88K	44.14K
Pretax Income+	-219.36K	-7.39M	-3.88M	-9.46M	-14.5M	-15.27M	-18.85M	-14.86M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	2.4%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-526.47K	-7.39M	-3.88M	-9.46M	-14.5M	-15.27M	-18.85M	-14.86M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-13.04%	0.48%	-1.44%	-0.53%	-0.05%	-0.23%	0.21%
Net Income (Continuing)	-219.36K	-7.39M	-3.88M	-9.46M	-14.5M	-15.27M	-18.85M	-14.86M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-576.12	-8088.84	-3.36	-6.84	-6.36	-134.64	-60.00	-38.87
EPS Growth %	-	-13.04%	1%	-1.04%	0.07%	-20.17%	0.55%	0.35%
EPS (Basic)	-576.12	-8088.84	-3.36	-6.84	-6.36	-134.64	-60.00	-38.87
Diluted Shares Outstanding	910.18K	910.18K	910.18K	919.56K	1.46M	2.26M	6.22M	317.26K
Basic Shares Outstanding	910.18K	910.18K	910.18K	913K	1.41M	2.26M	6.22M	317.26K
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	162.19K	588.13K	7.89M	15.5M	7.48M	12.56M	1.59M	8.66M
Cash & Short-Term Investments	110.54K	282.74K	7.24M	14.04M	5M	10.06M	548.72K	6.46M
Cash Only	110.54K	282.74K	7.24M	14.04M	5M	10.06M	548.72K	6.46M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	882.54K
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	272.4K	0	0	0	0	202.86K	1.31M
Total Non-Current Assets+	0	95.2K	18.16K	357.57K	1.28M	488.47K	109.68K	42.44K
Property, Plant & Equipment	0	0	18.16K	23.43K	16.11K	5.66K	4.93K	6K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	95.2K	0	334.14K	1.26M	482.81K	104.75K	36.43K
Total Assets+	162.19K	683.33K	7.91M	15.85M	8.76M	13.05M	1.7M	8.7M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	3.21%	10.58%	1%	-0.45%	0.49%	-0.87%	4.12%
Total Current Liabilities+	220.73K	1.23M	311K	1.91M	2.14M	4.92M	6.13M	2.52M
Accounts Payable	57.5K	128.87K	289.5K	946.33K	1.52M	3.68M	5.83M	2.2M
Days Payables Outstanding	-	-	54.05K	31.13K	42.53K	114.32K	514.93K	242.7K
Short-Term Debt	121.83K	316.92K	0	439.29K	387.79K	409.97K	300.81K	326.07K
Deferred Revenue (Current)	0	23.6K	0	0	0	0	0	0
Other Current Liabilities	0	739.65K	0	0	0	0	0	0
Current Ratio	0.73x	0.48x	25.38x	8.13x	3.50x	2.55x	0.26x	3.43x
Quick Ratio	0.73x	0.48x	25.38x	8.13x	3.50x	2.55x	0.26x	3.43x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	289.5K	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	220.73K	1.23M	311K	1.91M	2.14M	4.92M	6.13M	2.52M
Total Debt+	121.83K	316.92K	0	439.29K	387.79K	409.97K	300.81K	326.07K
Net Debt	11.28K	34.18K	-7.24M	-13.6M	-4.62M	-9.65M	-247.91K	-6.14M
Debt / Equity	-	-	-	0.03x	0.06x	0.05x	-	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-121.27x	-18.88x	-86.65x	-2896.63x	-1560.14x	-2125.08x	-1366.54x	-924.50x
Total Equity+	-58.53K	-549.3K	7.6M	13.95M	6.62M	8.13M	-4.43M	6.18M
Equity Growth %	-	-8.38%	14.84%	0.84%	-0.53%	0.23%	-1.54%	2.39%
Book Value per Share	-0.06	-0.60	8.35	15.17	4.54	3.60	-0.71	19.47
Total Shareholders' Equity	-58.53K	-549.3K	7.6M	13.95M	6.62M	8.13M	-4.43M	6.18M
Common Stock	10.27K	12.7K	16.45K	23.86K	27.93K	1.62K	6.21K	1.41K
Retained Earnings	-219.36K	-7.61M	-11.49M	-20.95M	-34.98M	-50.72M	-69.57M	-84.42M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-112.2K	-716.38K	-3.55M	-7.32M	-13.54M	-10.56M	-14.14M	-17.11M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-5.39%	-3.96%	-1.06%	-0.85%	0.22%	-0.34%	-0.21%
Net Income	-219.36K	-7.39M	-3.88M	-9.46M	-14.5M	-15.27M	-18.85M	-14.86M
Depreciation & Amortization	2.34K	0	1.96K	11.1K	13.07K	11.76K	4.13K	3.31K
Stock-Based Compensation	119.85K	110.24K	477.1K	1.29M	1.72M	1.2M	1.01M	838.96K
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	-62.28K	6.48M	270.31K	1.58K	0	337.25K	498	596.11K
Working Capital Changes	47.25K	83.78K	-425.62K	833.78K	-780.02K	3.16M	3.7M	-3.69M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	57.5K	71.37K	153.61K	656.83K	1.04M	1.7M	1.32M	-3.63M
Cash from Investing+	0	0	-20.12K	-17.95K	-5.75K	-4.42K	-3.9K	-4.19K
Capital Expenditures	0	0	-20.12K	-17.95K	-5.75K	-4.42K	-3.9K	-4.19K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing+	222.74K	1.16M	10.26M	14.13M	4.51M	15.61M	4.64M	23.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	470.48K	0	-45K	332.75K	2.73K	2.76M	-45.42K
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-112.2K	-716.38K	-3.57M	-7.34M	-13.54M	-10.56M	-14.14M	-17.12M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-5.39%	-3.99%	-1.05%	-0.85%	0.22%	-0.34%	-0.21%
FCF per Share	-0.12	-0.79	-3.93	-7.98	-9.29	-4.67	-2.27	-53.95
FCF Conversion (FCF/Net Income)	0.21x	0.10x	0.92x	0.77x	0.93x	0.69x	0.75x	1.15x
Interest Paid	0	0	0	0	9.77K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-109.96%	-87.78%	-140.94%	-207.04%	-1018.78%	-1703.39%
Return on Invested Capital (ROIC)	-	-	-	-2004.3%	-923.5%	-4547.99%	-	-
Debt / Equity	-	-	-	0.03x	0.06x	0.05x	-	0.05x
Interest Coverage	-121.27x	-18.88x	-86.65x	-2896.63x	-1560.14x	-2125.08x	-1366.54x	-924.50x
FCF Conversion	0.21x	0.10x	0.92x	0.77x	0.93x	0.69x	0.75x	1.15x

Frequently Asked Questions

Growth & Financials

CNS Pharmaceuticals, Inc. (CNSP) grew revenue by 0.0% over the past year. Growth has been modest.

CNS Pharmaceuticals, Inc. (CNSP) reported a net loss of $13.1M for fiscal year 2024.

Dividend & Returns

CNS Pharmaceuticals, Inc. (CNSP) has a return on equity (ROE) of -1703.4%. Negative ROE indicates the company is unprofitable.

CNS Pharmaceuticals, Inc. (CNSP) had negative free cash flow of $16.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

CNS Pharmaceuticals, Inc. (CNSP) 10-Year Financial Performance & Capital Metrics

CNSP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$15M +21.0%
Net Income -$15M +21.2%
EPS (Diluted) -38.87 +35.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -1703.39% -67.2%
ROIC -
Debt/Equity 0.05
Interest Coverage -924.50 +32.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Share count reduced 94.9% through buybacks
✓Trading at only 0.3x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM23.37%

EPS CAGR

10Y-

5Y-

3Y-

TTM79.36%

ROCE

10Y Avg-544.62%

5Y Avg-631.8%

3Y Avg-976.8%

Latest-1708.45%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.55B	7.62	54.43	55.85%	3.98%	15.63%	0.35%	1.02
EXELExelixis, Inc.	12.13B	45.23	25.70	18.49%	29.63%	31.37%	5.23%	0.09
INBXInhibrx Biosciences, Inc.	1.1B	75.93	0.65	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.16B	6.31	-2.99		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.4B	8.07	-3.42	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.1B	11.25	-6.15			-33.24%		0.01
ZLABZai Lab Limited	2.17B	19.61	-7.54	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.67B	12.39	-10.41	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	1.96K	11.1K	13.07K	11.76K	4.13K	3.31K
COGS % of Revenue	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-1.96K	-11.1K	-13.07K	-11.76K	-4.13K	-3.31K
Gross Margin %	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-4.68%	-0.18%	0.1%	0.65%	0.2%
Operating Expenses+	215.1K	881.79K	3.83M	9.44M	14.47M	14.92M	18.86M	14.9M
OpEx % of Revenue	-	-	-	-	-	-	-	-
Selling, General & Admin	182.47K	860.52K	1.98M	4.38M	4.67M	5.62M	4.77M	5.61M
SG&A % of Revenue	-	-	-	-	-	-	-	-
Research & Development	32.64K	21.27K	1.85M	5.06M	9.81M	9.3M	14.1M	9.29M
R&D % of Revenue	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	-4.13K	0
Operating Income+	-516.25K	-881.79K	-3.83M	-9.45M	-14.49M	-14.93M	-18.87M	-14.9M
Operating Margin %	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.71%	-3.35%	-1.47%	-0.53%	-0.03%	-0.26%	0.21%
EBITDA+	0	0	-3.83M	-9.44M	-14.47M	-14.92M	-18.86M	-14.9M
EBITDA Margin %	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-	-	-1.47%	-0.53%	-0.03%	-0.26%	0.21%
D&A (Non-Cash Add-back)	516.25K	881.79K	1.96K	11.1K	13.07K	11.76K	4.13K	3.31K
EBIT	-516.25K	-7.35M	-3.83M	-9.45M	-14.49M	-15.27M	-18.87M	-14.84M
Net Interest Income+	-4.26K	-46.7K	-44.23K	-3.26K	-9.28K	-7.03K	13.88K	44.14K
Interest Income	0	0	44	3	9	7	27.69K	60.26K
Interest Expense	4.26K	46.7K	44.23K	3.26K	9.29K	7.03K	13.8K	16.12K
Other Income/Expense	-4.26K	-6.51M	-44.23K	-3.26K	-9.29K	-341.17K	13.88K	44.14K
Pretax Income+	-219.36K	-7.39M	-3.88M	-9.46M	-14.5M	-15.27M	-18.85M	-14.86M
Pretax Margin %	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	2.4%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-526.47K	-7.39M	-3.88M	-9.46M	-14.5M	-15.27M	-18.85M	-14.86M
Net Margin %	-	-	-	-	-	-	-	-
Net Income Growth %	-	-13.04%	0.48%	-1.44%	-0.53%	-0.05%	-0.23%	0.21%
Net Income (Continuing)	-219.36K	-7.39M	-3.88M	-9.46M	-14.5M	-15.27M	-18.85M	-14.86M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-576.12	-8088.84	-3.36	-6.84	-6.36	-134.64	-60.00	-38.87
EPS Growth %	-	-13.04%	1%	-1.04%	0.07%	-20.17%	0.55%	0.35%
EPS (Basic)	-576.12	-8088.84	-3.36	-6.84	-6.36	-134.64	-60.00	-38.87
Diluted Shares Outstanding	910.18K	910.18K	910.18K	919.56K	1.46M	2.26M	6.22M	317.26K
Basic Shares Outstanding	910.18K	910.18K	910.18K	913K	1.41M	2.26M	6.22M	317.26K
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	162.19K	588.13K	7.89M	15.5M	7.48M	12.56M	1.59M	8.66M
Cash & Short-Term Investments	110.54K	282.74K	7.24M	14.04M	5M	10.06M	548.72K	6.46M
Cash Only	110.54K	282.74K	7.24M	14.04M	5M	10.06M	548.72K	6.46M
Short-Term Investments	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	882.54K
Days Sales Outstanding	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	272.4K	0	0	0	0	202.86K	1.31M
Total Non-Current Assets+	0	95.2K	18.16K	357.57K	1.28M	488.47K	109.68K	42.44K
Property, Plant & Equipment	0	0	18.16K	23.43K	16.11K	5.66K	4.93K	6K
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	95.2K	0	334.14K	1.26M	482.81K	104.75K	36.43K
Total Assets+	162.19K	683.33K	7.91M	15.85M	8.76M	13.05M	1.7M	8.7M
Asset Turnover	-	-	-	-	-	-	-	-
Asset Growth %	-	3.21%	10.58%	1%	-0.45%	0.49%	-0.87%	4.12%
Total Current Liabilities+	220.73K	1.23M	311K	1.91M	2.14M	4.92M	6.13M	2.52M
Accounts Payable	57.5K	128.87K	289.5K	946.33K	1.52M	3.68M	5.83M	2.2M
Days Payables Outstanding	-	-	54.05K	31.13K	42.53K	114.32K	514.93K	242.7K
Short-Term Debt	121.83K	316.92K	0	439.29K	387.79K	409.97K	300.81K	326.07K
Deferred Revenue (Current)	0	23.6K	0	0	0	0	0	0
Other Current Liabilities	0	739.65K	0	0	0	0	0	0
Current Ratio	0.73x	0.48x	25.38x	8.13x	3.50x	2.55x	0.26x	3.43x
Quick Ratio	0.73x	0.48x	25.38x	8.13x	3.50x	2.55x	0.26x	3.43x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	289.5K	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0
Total Liabilities	220.73K	1.23M	311K	1.91M	2.14M	4.92M	6.13M	2.52M
Total Debt+	121.83K	316.92K	0	439.29K	387.79K	409.97K	300.81K	326.07K
Net Debt	11.28K	34.18K	-7.24M	-13.6M	-4.62M	-9.65M	-247.91K	-6.14M
Debt / Equity	-	-	-	0.03x	0.06x	0.05x	-	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-121.27x	-18.88x	-86.65x	-2896.63x	-1560.14x	-2125.08x	-1366.54x	-924.50x
Total Equity+	-58.53K	-549.3K	7.6M	13.95M	6.62M	8.13M	-4.43M	6.18M
Equity Growth %	-	-8.38%	14.84%	0.84%	-0.53%	0.23%	-1.54%	2.39%
Book Value per Share	-0.06	-0.60	8.35	15.17	4.54	3.60	-0.71	19.47
Total Shareholders' Equity	-58.53K	-549.3K	7.6M	13.95M	6.62M	8.13M	-4.43M	6.18M
Common Stock	10.27K	12.7K	16.45K	23.86K	27.93K	1.62K	6.21K	1.41K
Retained Earnings	-219.36K	-7.61M	-11.49M	-20.95M	-34.98M	-50.72M	-69.57M	-84.42M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-112.2K	-716.38K	-3.55M	-7.32M	-13.54M	-10.56M	-14.14M	-17.11M
Operating CF Margin %	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-5.39%	-3.96%	-1.06%	-0.85%	0.22%	-0.34%	-0.21%
Net Income	-219.36K	-7.39M	-3.88M	-9.46M	-14.5M	-15.27M	-18.85M	-14.86M
Depreciation & Amortization	2.34K	0	1.96K	11.1K	13.07K	11.76K	4.13K	3.31K
Stock-Based Compensation	119.85K	110.24K	477.1K	1.29M	1.72M	1.2M	1.01M	838.96K
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	-62.28K	6.48M	270.31K	1.58K	0	337.25K	498	596.11K
Working Capital Changes	47.25K	83.78K	-425.62K	833.78K	-780.02K	3.16M	3.7M	-3.69M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	57.5K	71.37K	153.61K	656.83K	1.04M	1.7M	1.32M	-3.63M
Cash from Investing+	0	0	-20.12K	-17.95K	-5.75K	-4.42K	-3.9K	-4.19K
Capital Expenditures	0	0	-20.12K	-17.95K	-5.75K	-4.42K	-3.9K	-4.19K
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0
Cash from Financing+	222.74K	1.16M	10.26M	14.13M	4.51M	15.61M	4.64M	23.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	0	470.48K	0	-45K	332.75K	2.73K	2.76M	-45.42K
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-112.2K	-716.38K	-3.57M	-7.34M	-13.54M	-10.56M	-14.14M	-17.12M
FCF Margin %	-	-	-	-	-	-	-	-
FCF Growth %	-	-5.39%	-3.99%	-1.05%	-0.85%	0.22%	-0.34%	-0.21%
FCF per Share	-0.12	-0.79	-3.93	-7.98	-9.29	-4.67	-2.27	-53.95
FCF Conversion (FCF/Net Income)	0.21x	0.10x	0.92x	0.77x	0.93x	0.69x	0.75x	1.15x
Interest Paid	0	0	0	0	9.77K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-109.96%	-87.78%	-140.94%	-207.04%	-1018.78%	-1703.39%
Return on Invested Capital (ROIC)	-	-	-	-2004.3%	-923.5%	-4547.99%	-	-
Debt / Equity	-	-	-	0.03x	0.06x	0.05x	-	0.05x
Interest Coverage	-121.27x	-18.88x	-86.65x	-2896.63x	-1560.14x	-2125.08x	-1366.54x	-924.50x
FCF Conversion	0.21x	0.10x	0.92x	0.77x	0.93x	0.69x	0.75x	1.15x

Frequently Asked Questions

Growth & Financials

CNS Pharmaceuticals, Inc. (CNSP) grew revenue by 0.0% over the past year. Growth has been modest.

CNS Pharmaceuticals, Inc. (CNSP) reported a net loss of $13.1M for fiscal year 2024.

Dividend & Returns

CNS Pharmaceuticals, Inc. (CNSP) has a return on equity (ROE) of -1703.4%. Negative ROE indicates the company is unprofitable.

CNS Pharmaceuticals, Inc. (CNSP) had negative free cash flow of $16.2M in fiscal year 2024, likely due to heavy capital investments.